Why Did MedPlus Health’s Shares Drop Over 3%?
Click to start listening
Synopsis
On October 13, MedPlus Health Services saw a notable decline in shares, plummeting over 3.6% on the BSE following the suspension of a drug license at a subsidiary store. This article delves into the implications of this suspension and what it means for the company’s future.
Key Takeaways
- MedPlus shares fell by 3.6% after a drug license suspension.
- Optival Health Solutions is the affected subsidiary.
- The suspension is for 15 days and could lead to a loss of Rs 10.15 lakh.
- CareEdge reaffirmed a ‘CARE A’ rating for the company.
- MedPlus operates over 4,230 stores across India.
Mumbai, Oct 13 (NationPress) Shares of MedPlus Health Services experienced a decline of over 3.6 percent on the BSE, hitting an intra-day low of Rs 755.3 per share on Monday.
Later in the trading session, the stock rebounded, settling at Rs 765 per share, which is 2.42 percent lower. The company's market capitalization is currently at Rs 9,166.43 crore.
This drop in MedPlus shares occurred following the suspension of a drug license for its subsidiary, Optival Health Solutions Private Limited, at a store in Karnataka.
A filing with the stock exchange indicated that the suspension would last for 15 days for the store located on MG Road, Chikkamagalore, potentially resulting in a revenue loss of Rs 10.15 lakh.
The company stated, 'We would like to inform you that Optival Health Solutions Private Limited, a subsidiary of the company, has received a suspension order for a Drug License of a store situated in Karnataka.'
This incident is not isolated; previously, on October 9, a store in Alaknanda Colony, Vizianagaram, Andhra Pradesh, was suspended for a period of seven days.
Moreover, several stores in Chhattisgarh and Telangana have also encountered temporary drug license suspensions.
Despite these challenges, CareEdge Ratings has recently reaffirmed its confidence in the company’s financial stability.
On October 10, CareEdge maintained a ‘CARE A’ rating for Optival Health Solutions’ long-term bank facilities worth Rs 236 crore (up from Rs 200 crore) with a ‘Stable’ outlook.
For short-term bank facilities amounting to Rs 14 crore (up from Rs 12 crore), the agency reaffirmed the ‘CARE A1’ rating.
MedPlus Health Services operates one of India’s largest pharmacy retail networks, boasting over 4,230 stores across 600 cities in 10 states, including Tamil Nadu, Andhra Pradesh, Telangana, Karnataka, Odisha, West Bengal, Maharashtra, Kerala, Chhattisgarh, and Madhya Pradesh.
This company’s operations encompass retail and wholesale activities, manufacturing of private-label products, imports, distribution, and diagnostic services.
Point of View
The recent suspension of drug licenses affecting MedPlus Health Services raises concerns about regulatory compliance in the pharmaceutical sector. However, the company's strong market presence and the reaffirmed ratings from CareEdge Ratings suggest resilience amidst challenges. It is crucial for stakeholders to monitor developments closely as the situation unfolds.
NationPress
13/10/2025
Frequently Asked Questions
What caused the drop in MedPlus shares?
The decline was primarily due to a suspension order for a drug license at a subsidiary store in Karnataka.
How long will the drug license suspension last?
The suspension will be in effect for 15 days.
What is the potential revenue loss from this suspension?
The estimated revenue loss is around Rs 10.15 lakh.
Has MedPlus faced similar issues in the past?
Yes, previous suspensions have occurred at other stores in Andhra Pradesh, Chhattisgarh, and Telangana.
What is the current rating for Optival Health Solutions?
CareEdge Ratings has maintained a ‘CARE A’ rating for its long-term bank facilities.
